**Author details**

Febina Ravindran\* and Bibha Choudhary Institute of Bioinformatics and Applied Biotechnology, Bangalore, India

\*Address all correspondence to: vibha@ibab.ac.in

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**15**

599-612.

*Ovarian Cancer: Molecular Classification and Targeted Therapy*

meta-analysis of 52 epidemiological studies. Lancet 2015; 385: 1835-1842.

[11] Pearce CL, Templeman C,

[13] Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@ asrm.org, Practice Committee of the American Society for Reproductive Medicine. Fertility drugs and cancer: a guideline. Fertil Steril 2016; 106:

[14] Wentzensen N, Poole EM, Trabert B, et al. Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium. J Clin Oncol 2016;

[15] Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, et al. The risk of breast and gynecological cancer in women with a diagnosis of infertility: A nationwide population-based study. Eur

J Epidemiol 2019; 34: 499-507.

[16] McGuire V, Hartge P, Liao LM, et al. Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women. Cancer Epidemiol Biomarkers Prev 2016; 25: 1059-1063.

Oncol 2012; 13: 385-394.

1181-1187.

1617-1626.

34: 2888-2898.

[10] Trabert B, Wentzensen N, Yang HP, et al. Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 2012; 107:

Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet

[12] D Farhud D, Zokaei S, Keykhaei M, et al. Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article. Iran J Public Health 2019; 48: 2124-2132.

*DOI: http://dx.doi.org/10.5772/intechopen.95967*

[1] Swerdlow M. Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol 1959; 77:

[2] Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell

Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144:

[4] Shabir S, Gill PK. Global scenario on ovarian cancer – Its dynamics, relative survival, treatment, and epidemiology.

[5] Mohammadian M, Ghafari M, Khosravi B, et al. Variations in the Incidence and Mortality of Ovarian Cancer and Their Relationship with the Human Development Index in European Countries in 2012. Biomedical Research

[6] Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. CA

[7] Nielsen FC, van Overeem Hansen T, Sørensen CS. Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 2016; 16:

[8] Nakamura K, Banno K, Yanokura M, et al. Features of ovarian cancer in Lynch syndrome (Review). Mol Clin

Cancer J Clin 2018; 68: 284-296.

Proteomics 2004; 3: 355-366.

[3] Ferlay J, Colombet M,

AUJMSR 2020; 2: 17-25.

and Therapy 2017; 4: 1541.

Oncol 2014; 2: 909-916.

[9] Collaborative Group On

Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, et al. Menopausal hormone use and ovarian cancer risk: individual participant

**References**

197-200.

1941-1953.

*Ovarian Cancer: Molecular Classification and Targeted Therapy DOI: http://dx.doi.org/10.5772/intechopen.95967*
